QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.104.006569v1 67/1/60    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bauman, D. R. Articles by Penning, T. M. Search for Related Content PubMed PubMed Citation Articles by Bauman, D. R. Articles by Penning, T. M.

Development of Nonsteroidal Anti-Inflammatory Drug Analogs and Steroid Carboxylates Selective for Human Aldo-Keto Reductase Isoforms: Potential Antineoplastic Agents That Work Independently of Cyclooxygenase Isozymes

Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Human aldo-keto reductases (AKRs) regulate nuclear receptors by controlling ligand availability. Enzymes implicated in regulating ligand occupancy and trans-activation of the nuclear receptors belong to the AKR1C family (AKR1C1-AKR1C3). Nuclear receptors regulated by AKR1C members include the steroid hormone receptors (androgen, estrogen, and progesterone receptors) and the orphan peroxisome proliferator-activated receptor (PPAR). In human myeloid leukemia (HL-60) cells, ligand access to PPAR is regulated by AKR1C3, which diverts PGD₂ metabolism away from J-series prostanoids (Desmond et al., 2003). Inhibition of AKR1C3 by indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), caused PPAR-mediated terminal differentiation of the HL-60 cells. To discriminate between antineoplastic effects of NSAIDs that are mediated by either AKR1C or cyclooxygenase (COX) isozymes, selective inhibitors are required. We report a structural series of N-phenylanthranilic acid derivatives and steroid carboxylates that selectively inhibit recombinant AKR1C isoforms but do not inhibit recombinant COX-1 or COX-2. The inhibition constants, IC₅₀, K_I values, and inhibition patterns were determined for the NSAID analogs and steroid carboxylates against AKR1C and COX isozymes. Lead compounds, 4-chloro-N-phenylanthranilic acid and 4-benzoyl-benzoic acid for the N-phenylanthranilic acid analogs and most steroid carboxylates, exhibited IC₅₀ values that had greater than 500-fold selectivity for AKR1C isozymes compared with COX-1 and COX-2. Crystallographic and molecular modeling studies showed that the carboxylic acid of the inhibitor ligand was tethered by the catalytic Tyr55-OH₂⁺ and explained why A-ring substituted N-phenylanthranilates inhibited only AKR1C enzymes. These compounds can be used to dissect the role of the AKR1C isozymes in neoplastic diseases and may have cancer chemopreventive roles independent of COX inhibition.

Received for publication August 26, 2004.

Accepted for publication October 5, 2004.

Address correspondence to: Dr. Trevor M. Penning, Department of Pharmacology, University of Pennsylvania School of Medicine, 130C John Morgan Building, 3620 Hamilton Walk, Philadelphia, PA 19104-6084. E-mail: penning{at}pharm.med.upenn.edu

This article has been cited by other articles:

				C.-W. Chien, I-C. Ho, and T.-C. Lee Induction of neoplastic transformation by ectopic expression of human aldo-keto reductase 1C isoforms in NIH3T3 cells Carcinogenesis, October 1, 2009; 30(10): 1813 - 1820. [Abstract] [Full Text] [PDF]

				Y. Nakamura, P. J. Hornsby, P. Casson, R. Morimoto, F. Satoh, Y. Xing, M. R. Kennedy, H. Sasano, and W. E. Rainey Type 5 17{beta}-Hydroxysteroid Dehydrogenase (AKR1C3) Contributes to Testosterone Production in the Adrenal Reticularis J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2192 - 2198. [Abstract] [Full Text] [PDF]

				J. M Day, H. J Tutill, A. Purohit, and M. J Reed Design and validation of specific inhibitors of 17{beta}-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis Endocr. Relat. Cancer, September 1, 2008; 15(3): 665 - 692. [Abstract] [Full Text] [PDF]

				B. L Dozier, K. Watanabe, and D. M Duffy Two pathways for prostaglandin F2{alpha} synthesis by the primate periovulatory follicle Reproduction, July 1, 2008; 136(1): 53 - 63. [Abstract] [Full Text] [PDF]

				W. Qiu, M. Zhou, M. Mazumdar, A. Azzi, D. Ghanmi, V. Luu-The, F. Labrie, and S.-X. Lin Structure-based Inhibitor Design for an Enzyme That Binds Different Steroids: A POTENT INHIBITOR FOR HUMAN TYPE 5 17beta-HYDROXYSTEROID DEHYDROGENASE J. Biol. Chem., March 16, 2007; 282(11): 8368 - 8379. [Abstract] [Full Text] [PDF]

				D. J. Yee, V. Balsanek, D. R. Bauman, T. M. Penning, and D. Sames Fluorogenic metabolic probes for direct activity readout of redox enzymes: Selective measurement of human AKR1C2 in living cells PNAS, September 5, 2006; 103(36): 13304 - 13309. [Abstract] [Full Text] [PDF]